SILOHealthcare · Biotechnology

SILO Stock Forecast: Silo Pharma, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026

$1.84

+6.98% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 19 Sept 2026 — in the weakest quartile.

Market cap

$3.2M

Ticker Nerd rank

24 / 100

Median analyst target

—

Analysts covering

Revenue$0.0−100.0% y/y

Operating income−$929K

Net income−$833K

Free cash flow−$732K

Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown

Total return, dividends reinvested

−12.4%

−40.1%

YTD

−63.9%

−82.6%

From 52W high

−84.9%

From 52W low

+7.0%

$12

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

SILO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Silo Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026

24 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Growth

Accruals

Volatility

Issuance

Revisions

Momentum

Quality

Value

Size (98): Smaller than most of the companies we track.

Value (6): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SILO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SILO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
28 Aug 2023	Laidlaw & Co.	Initiates	Buy	$10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SILO appears on the weeks it earns a place.

Performance

SILO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 18 Sept 2026, Silo Pharma, Inc. returned −82.6% against +16.3% for the S&P 500, dividends included.

SILO vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SILO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Silo Pharma, Inc. (SILO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.2×
Price / sales: 59.7×
Price / book: 0.4×
EV / EBITDA: 0.5×

Growth & margins

Revenue growth (YoY): −100.0%
Earnings growth (YoY): −100.0%
Gross margin: −14.8%
Operating margin: −8250.5%
Net margin: 38.6%

Returns & dividend

Return on equity: −91.2%
Return on assets: −44.2%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Silo Pharma, Inc. (SILO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Silo Pharma, Inc. has a market value of $3.2M and an enterprise value of −$2.3M.
Revenue in the twelve months to 30 June 2026: $54K. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$4.5M, a −8269.5% net margin.
Free cash flow in the twelve months to 30 June 2026: −$3.9M.
Shares outstanding: 1.1M.
Trailing P/E: −0.2×; forward P/E: −2.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Silo Pharma, Inc. employs 3 people — $18K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 19 Sept 2026

Data provided by Twelve Data

Peers

SILO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
SILOSilo Pharma, Inc.	$3.2M	24
TCRTAlaunos Therapeutics, Inc.	$2.9M	28
BCABBioAtla, Inc.	$2.9M	—
CLDICalidi Biotherapeutics, Inc.	$2.8M	23
GNPXGenprex, Inc.	$2.8M	9
ONCOOnconetix, Inc.	$2.8M	16
CMNDClearmind Medicine, Inc.	$2.7M	6

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Silo Pharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SILO news & analysis

Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio

GlobeNewsWire · 18 Sept 2026positive

The USPTO issued a Notice of Allowance for a patent application covering Silo Pharma's lead asset, SPC-15, an intranasal therapeutic for PTSD. The allowed claims cover compositions and methods for preventing or mitigating stress-induced behavioral responses, expanding the company's intellectual property portfolio.

Why it matters — This patent allowance strengthens Silo Pharma's intellectual property protection for its lead PTSD candidate, SPC-15, which could be important for the company's development strategy.

Silo Pharma to Highlight Patented Nose-to-Brain Drug Delivery Technology for PTSD at 2026 Nasal Innovation Forum

GlobeNewsWire · 9 Sept 2026neutral

Silo Pharma announced that company representatives will participate in the IPAC-RS 2026 Nasal Innovation Forum, held September 16-17, 2026, in Jersey City, New Jersey, where they will highlight the company's patented nose-to-brain drug delivery technology for PTSD.

Why it matters — The forum participation gives Silo Pharma a platform to showcase its patented nose-to-brain delivery technology for PTSD, a key part of its drug delivery systems focus.

Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment

GlobeNewsWire · 18 Aug 2026positive

Silo Pharma announced it received a notice of allowance for a Canadian patent application covering its novel PTSD treatment. This follows a recent European patent grant and expands coverage in multiple international markets as the company strengthens its licensed IP portfolio for its lead therapeutic program.

Why it matters — A SILO watcher would care because expanding patent protection in Canada and Europe supports the intellectual property position of the company's lead PTSD treatment program.

Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform

GlobeNewsWire · 6 Aug 2026positive

Silo Pharma subsidiary QwikAgents has announced a collaboration with Caylent, an Amazon Web Services Premier Tier Partner, to advance an enterprise AI platform. The collaboration supports development of a next-generation AWS-native platform designed to accelerate commercialization, scalability, and enterprise adoption.

Why it matters — A SILO watcher would care because the collaboration positions QwikAgents' AWS-native AI platform for commercialization and broader enterprise adoption, potentially strengthening Silo Pharma's subsidiary operations.

FAQ

Frequently asked questions about SILO stock

How does Ticker Nerd's model rank SILO?

As at 19 Sept 2026, Silo Pharma, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the SILO stock forecast for 2030?

No analyst covering Silo Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SILO are extrapolating price history, which says nothing about the business.

How has SILO stock performed over the past year?

Silo Pharma, Inc. returned -82.6% over the 12 months to 18 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Silo Pharma, Inc. do?

What is the latest news on SILO?

The most recent item we track (GlobeNewsWire, 18 Sept 2026): "Silo Pharma Receives U.S. Patent Allowance for SPC-15 PTSD Treatment, Expanding Intellectual Property Portfolio". The USPTO issued a Notice of Allowance for a patent application covering Silo Pharma's lead asset, SPC-15, an intranasal therapeutic for PTSD. The allowed claims cover compositions and methods for preventing or mitigating stress-induced behavioral responses, expanding the company's intellectual property portfolio.

Company

About Silo Pharma, Inc.

Silo Pharma Inc. is a developmental stage biopharmaceutical company focused on developing novel therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, chronic pain, and central nervous system diseases such as Alzheimer's and multiple sclerosis. The company merges traditional therapies with psychedelic medicine, utilizing innovative formulations and drug delivery systems like intranasal treatments and time-release implants. Its lead program, SPC-15, is an intranasal formulation targeting PTSD and stress-induced anxiety. SP-26 is a ketamine-based injectable dissolvable implant designed for fibromyalgia and chronic pain relief. Preclinical efforts include SPC-14, an intranasal compound for Alzheimer's disease, and SPU-16, a CNS-homing peptide for multiple sclerosis. Silo Pharma acquires intellectual property from universities and researchers, pursuing streamlined clinical pathways. Founded in 2010 and headquartered in Sarasota, Florida, the company partners with leading academic institutions to advance its pipeline of psychedelic and conventional treatments for psychiatric and neurological disorders.

CEO Mr. Eric Weisblum · 3 employees · United States · https://silopharma.com